- The shares of Becton Dickinson (NYSE: BDX) have received a $290 price target from BofA Securities. These are the details.
The shares of Becton Dickinson (NYSE: BDX) have received a $290 price target from BofA Securities. And BofA Securities analyst Travis Steed reinstated coverage on Becton Dickinson with a “Neutral” rating.
“BDX appears to be back to executing and delivering a consistent message and BDX also has some of the best pricing power in medtech on a relative basis (+1.1% price last qtr),” wrote Steed in a research note. “We now have more confidence in BDX delivering on its core targets with 17 higher growth/higher margin acquisitions over the last 2 years that move BDX to take advantage of the new thematic shifts in healthcare (connected care / shift out of hospital). Despite all these positives, we rate shares Neutral as EPS needs to move lower for the diabetes spin and valuation is at a level where we do not get material upside.”
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.